Biotechnology Firm Amgen Declares 3-for-1 Stock Split

Amgen Inc., a Thousand Oaks-based biotechnology concern, declared a 3-for-1 stock split to be distributed Sept. 10 to stockholders of record Aug. 30.

The company’s board also changed Amgen’s fiscal year-end to Dec. 31 from March 31, effective immediately.

Amgen’s stock, which closed Monday at $144.75 a share in national over-the-counter trading, has more than quadrupled in price since the end of 1989, as the company’s initial drugs have reached the marketplace and triggered sharp gains in Amgen’s growth. The company had one earlier 2-for-1 stock split in June, 1990.